{
  "id": 16999182,
  "title": "TB Alliance fails to get patent for six-month treatment regimen",
  "url": "https://urgent.news/2026/10/29/tb-alliance-fails-to-get-patent-for-six-month-treatment-regimen",
  "topic": "world",
  "section": "World",
  "published": "2026-10-29T02:25:00.000Z",
  "source": {
    "name": "Hindustan Times",
    "slug": "hindustan-times",
    "url": "https://www.hindustantimes.com/india-news/tb-alliance-fails-to-get-patent-for-six-month-treatment-regimen-101793215103983.html"
  },
  "original_language": "en",
  "account": null,
  "summary": "The Indian Patent Office on Tuesday rejected a patent application for BPaL, a combination of three medicines that has cut treatment for drug-resistant tuberculosis (TB) to six months, according to a joint statement by the groups that opposed it",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}